Loading...

Almira Correia, PhD

Title(s)Professor, Cellular Molecular Pharmacology
SchoolSchool of Medicine
Phone415-476-3992
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Hepatic degradation of cytochrome P450 enzymes
    NIH R01GM044037Apr 1, 1990 - May 31, 2019
    Role: Principal Investigator
    GORDON RESEARCH CONFERENCE-CHEMISTRY/BIOLOGY OF PYRROLES
    NIH R13DK040470May 1, 1988 - Apr 30, 1989
    Role: Principal Investigator
    Bio-Organic Biomedical Mass Spectrometry Resource
    NIH P41RR001614Mar 1, 1982 - May 31, 2015
    Role: Co-Investigator
    Influence of Heme on Hepatic Cytochrome P450 Turnover
    NIH R01DK026506Jul 1, 1980 - Mar 31, 2017
    Role: Principal Investigator
    Influence of Heme on Hepatic Cytochrome P450 Synthesis and Degradation
    NIH R56DK026506Jul 1, 1980 - Jun 30, 2008
    Role: Principal Investigator
    REGULATION OF HEME METABOLISM IN THE LIVER
    NIH R01AM026506Jul 1, 1980 - Jun 30, 1986
    Role: Principal Investigator
    MASS SPECTROMETRY
    NIH P41RR000480Jan 1, 1978 - Nov 30, 1999
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Global Health
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Lewis-Ballester A, Forouhar F, Kim SM, Lew S, Wang Y, Karkashon S, Seetharaman J, Batabyal D, Chiang BY, Hussain M, Correia MA, Yeh SR, Tong L. Molecular basis for catalysis and substrate-mediated cellular stabilization of human tryptophan 2,3-dioxygenase. Sci Rep. 2016 10 20; 6:35169. PMID: 27762317.
      View in: PubMed
    2. Kim SM, Grenert JP, Patterson C, Correia MA. CHIP(-/-)-Mouse Liver: Adiponectin-AMPK-FOXO-Activation Overrides CYP2E1-Elicited JNK1-Activation, Delaying Onset of NASH: Therapeutic Implications. Sci Rep. 2016 07 12; 6:29423. PMID: 27406999.
      View in: PubMed
    3. Kim SM, Wang Y, Nabavi N, Liu Y, Correia MA. Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame. Drug Metab Rev. 2016 08; 48(3):405-33. PMID: 27320797.
      View in: PubMed
    4. Wang Y, Kim SM, Trnka MJ, Liu Y, Burlingame AL, Correia MA. Human liver cytochrome P450 3A4 ubiquitination: molecular recognition by UBC7-gp78 autocrine motility factor receptor and UbcH5a-CHIP-Hsc70-Hsp40 E2-E3 ubiquitin ligase complexes. J Biol Chem. 2015 Feb 06; 290(6):3308-32. PMID: 25451919.
      View in: PubMed
    5. Correia MA, Wang Y, Kim SM, Guan S. Hepatic cytochrome P450 ubiquitination: conformational phosphodegrons for E2/E3 recognition? IUBMB Life. 2014 Feb; 66(2):78-88. PMID: 24488826; PMCID: PMC3959620.
      View in: PubMed, PubMed Central
    6. Wang Y, Guan S, Acharya P, Liu Y, Thirumaran RK, Brandman R, Schuetz EG, Burlingame AL, Correia MA. Multisite phosphorylation of human liver cytochrome P450 3A4 enhances Its gp78- and CHIP-mediated ubiquitination: a pivotal role of its Ser-478 residue in the gp78-catalyzed reaction. Mol Cell Proteomics. 2012 Feb; 11(2):M111.010132. PMID: 22101235.
      View in: PubMed
    7. Wang Y, Guan S, Acharya P, Koop DR, Liu Y, Liao M, Burlingame AL, Correia MA. Ubiquitin-dependent proteasomal degradation of human liver cytochrome P450 2E1: identification of sites targeted for phosphorylation and ubiquitination. J Biol Chem. 2011 Mar 18; 286(11):9443-56. PMID: 21209460; PMCID: PMC3058980.
      View in: PubMed, PubMed Central
    8. Acharya P, Liao M, Engel JC, Correia MA. Liver cytochrome P450 3A endoplasmic reticulum-associated degradation: a major role for the p97 AAA ATPase in cytochrome P450 3A extraction into the cytosol. J Biol Chem. 2011 Feb 04; 286(5):3815-28. PMID: 21107009; PMCID: PMC3030383.
      View in: PubMed, PubMed Central
    9. Correia MA, Sinclair PR, De Matteis F. Cytochrome P450 regulation: the interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal. Drug Metab Rev. 2011 Feb; 43(1):1-26. PMID: 20860521; PMCID: PMC3034403.
      View in: PubMed, PubMed Central
    10. Kim SM, Acharya P, Engel JC, Correia MA. Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of Hsp70-interacting protein (CHIP) E3 ubiquitin ligases: physiological and pharmacological relevance. J Biol Chem. 2010 Nov 12; 285(46):35866-77. PMID: 20819951; PMCID: PMC2975210.
      View in: PubMed, PubMed Central
    11. Acharya P, Chen JJ, Correia MA. Hepatic heme-regulated inhibitor (HRI) eukaryotic initiation factor 2alpha kinase: a protagonist of heme-mediated translational control of CYP2B enzymes and a modulator of basal endoplasmic reticulum stress tone. Mol Pharmacol. 2010 Apr; 77(4):575-92. PMID: 20071449; PMCID: PMC2845940.
      View in: PubMed, PubMed Central
    12. Acharya P, Engel JC, Correia MA. Hepatic CYP3A suppression by high concentrations of proteasomal inhibitors: a consequence of endoplasmic reticulum (ER) stress induction, activation of RNA-dependent protein kinase-like ER-bound eukaryotic initiation factor 2alpha (eIF2alpha)-kinase (PERK) and general control nonderepressible-2 eIF2alpha kinase (GCN2), and global translational shutoff. Mol Pharmacol. 2009 Sep; 76(3):503-15. PMID: 19520899; PMCID: PMC2730383.
      View in: PubMed, PubMed Central
    13. Wang Y, Liao M, Hoe N, Acharya P, Deng C, Krutchinsky AN, Correia MA. A role for protein phosphorylation in cytochrome P450 3A4 ubiquitin-dependent proteasomal degradation. J Biol Chem. 2009 Feb 27; 284(9):5671-84. PMID: 19095658.
      View in: PubMed
    14. Pabarcus MK, Hoe N, Sadeghi S, Patterson C, Wiertz E, Correia MA. CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases. Arch Biochem Biophys. 2009 Mar 01; 483(1):66-74. PMID: 19103148.
      View in: PubMed
    15. Pearce RE, Lu W, Wang Y, Uetrecht JP, Correia MA, Leeder JS. Pathways of carbamazepine bioactivation in vitro. III. The role of human cytochrome P450 enzymes in the formation of 2,3-dihydroxycarbamazepine. Drug Metab Dispos. 2008 Aug; 36(8):1637-49. PMID: 18463198; PMCID: PMC2562787.
      View in: PubMed, PubMed Central
    16. Kang P, Liao M, Wester MR, Leeder JS, Pearce RE, Correia MA. CYP3A4-Mediated carbamazepine (CBZ) metabolism: formation of a covalent CBZ-CYP3A4 adduct and alteration of the enzyme kinetic profile. Drug Metab Dispos. 2008 Mar; 36(3):490-9. PMID: 18096676.
      View in: PubMed
    17. Liao M, Pabarcus MK, Wang Y, Hefner C, Maltby DA, Medzihradszky KF, Salas-Castillo SP, Yan J, Maher JJ, Correia MA. Impaired dexamethasone-mediated induction of tryptophan 2,3-dioxygenase in heme-deficient rat hepatocytes: translational control by a hepatic eIF2alpha kinase, the heme-regulated inhibitor. J Pharmacol Exp Ther. 2007 Dec; 323(3):979-89. PMID: 17761498.
      View in: PubMed
    18. Faouzi S, Medzihradszky KF, Hefner C, Maher JJ, Correia MA. Characterization of the physiological turnover of native and inactivated cytochromes P450 3A in cultured rat hepatocytes: a role for the cytosolic AAA ATPase p97? Biochemistry. 2007 Jul 03; 46(26):7793-803. PMID: 17550236; PMCID: PMC2536616.
      View in: PubMed, PubMed Central
    19. Correia MA, Liao M. Cellular proteolytic systems in P450 degradation: evolutionary conservation from Saccharomyces cerevisiae to mammalian liver. Expert Opin Drug Metab Toxicol. 2007 Feb; 3(1):33-49. PMID: 17269893.
      View in: PubMed
    20. Liao M, Faouzi S, Karyakin A, Correia MA. Endoplasmic reticulum-associated degradation of cytochrome P450 CYP3A4 in Saccharomyces cerevisiae: further characterization of cellular participants and structural determinants. Mol Pharmacol. 2006 Jun; 69(6):1897-904. PMID: 16556771.
      View in: PubMed
    21. Han XM, Lee G, Hefner C, Maher JJ, Correia MA. Heme-reversible impairment of CYP2B1/2 induction in heme-depleted rat hepatocytes in primary culture: translational control by a hepatic alpha-subunit of the eukaryotic initiation factor kinase? J Pharmacol Exp Ther. 2005 Jul; 314(1):128-38. PMID: 15769864.
      View in: PubMed
    22. Liao M, Zgoda VG, Zgoda VA, Murray BP, Correia MA. Vacuolar degradation of rat liver CYP2B1 in Saccharomyces cerevisiae: further validation of the yeast model and structural implications for the degradation of mammalian endoplasmic reticulum P450 proteins. Mol Pharmacol. 2005 May; 67(5):1460-9. PMID: 15703377.
      View in: PubMed
    23. Correia MA, Sadeghi S, Mundo-Paredes E. Cytochrome P450 ubiquitination: branding for the proteolytic slaughter? Annu Rev Pharmacol Toxicol. 2005; 45:439-64. PMID: 15822184.
      View in: PubMed
    24. Correia MA. Hepatic cytochrome P450 degradation: mechanistic diversity of the cellular sanitation brigade. Drug Metab Rev. 2003 May-Aug; 35(2-3):107-43. PMID: 12959413.
      View in: PubMed
    25. Stevens JC, Dean DC, Preusch PC, Correia MA. The changing environment of graduate and postdoctoral training in drug metabolism: viewpoints from academia, industry, and government. Drug Metab Dispos. 2003 Apr; 31(4):360-6. PMID: 12642460.
      View in: PubMed
    26. Xue L, Zgoda VG, Arison B, Correia MA. Structure-function relationships of rat liver CYP3A9 to its human liver orthologs: site-directed active site mutagenesis to a progesterone dihydroxylase. Arch Biochem Biophys. 2003 Jan 01; 409(1):113-26. PMID: 12464250.
      View in: PubMed
    27. Gavrilovich Zgoda V, Arison B, Mkrtchian S, Ingelman-Sundberg M, Correia MA. Hemin-mediated restoration of allylisopropylacetamide-inactivated CYP2B1: a role for glutathione and GRP94 in the heme-protein assembly. Arch Biochem Biophys. 2002 Dec 01; 408(1):58-68. PMID: 12485603.
      View in: PubMed
    28. Khan KK, He YQ, Correia MA, Halpert JR. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab Dispos. 2002 Sep; 30(9):985-90. PMID: 12167563.
      View in: PubMed
    29. Kresina TF, Flexner CW, Sinclair J, Correia MA, Stapleton JT, Adeniyi-Jones S, Cargill V, Cheever LW. Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses. 2002 Jul 20; 18(11):757-70. PMID: 12167267.
      View in: PubMed
    30. Murray BP, Zgoda VG, Correia MA. Native CYP2C11: heterologous expression in Saccharomyces cerevisiae reveals a role for vacuolar proteases rather than the proteasome system in the degradation of this endoplasmic reticulum protein. Mol Pharmacol. 2002 May; 61(5):1146-53. PMID: 11961133.
      View in: PubMed
    31. Wang X, Medzihradszky KF, Maltby D, Correia MA. Phosphorylation of native and heme-modified CYP3A4 by protein kinase C: a mass spectrometric characterization of the phosphorylated peptides. Biochemistry. 2001 Sep 25; 40(38):11318-26. PMID: 11560479.
      View in: PubMed
    32. Murray BP, Correia MA. Ubiquitin-dependent 26S proteasomal pathway: a role in the degradation of native human liver CYP3A4 expressed in Saccharomyces cerevisiae? Arch Biochem Biophys. 2001 Sep 01; 393(1):106-16. PMID: 11516167.
      View in: PubMed
    33. Dick R, Murray BP, Reid MJ, Correia MA. Structure--function relationships of rat hepatic tryptophan 2,3-dioxygenase: identification of the putative heme-ligating histidine residues. Arch Biochem Biophys. 2001 Aug 01; 392(1):71-8. PMID: 11469796.
      View in: PubMed
    34. Xue L, Wang HF, Wang Q, Szklarz GD, Domanski TL, Halpert JR, Correia MA. Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B(1) oxidation. Chem Res Toxicol. 2001 May; 14(5):483-91. PMID: 11368545.
      View in: PubMed
    35. Ren S, Correia MA. Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase? Arch Biochem Biophys. 2000 May 01; 377(1):195-203. PMID: 10775460.
      View in: PubMed
    36. Jäger W, Correia MA, Bornheim LM, Mahnke A, Hanstein WG, Xue L, Benet LZ. Ethynylestradiol-mediated induction of hepatic CYP3A9 in female rats: implication for cyclosporine metabolism. Drug Metab Dispos. 1999 Dec; 27(12):1505-11. PMID: 10570034.
      View in: PubMed
    37. Wang HF, Figueiredo Pereira ME, Correia MA. Cytochrome P450 3A degradation in isolated rat hepatocytes: 26S proteasome inhibitors as probes. Arch Biochem Biophys. 1999 May 01; 365(1):45-53. PMID: 10222037.
      View in: PubMed
    38. Korsmeyer KK, Davoll S, Figueiredo-Pereira ME, Correia MA. Proteolytic degradation of heme-modified hepatic cytochromes P450: A role for phosphorylation, ubiquitination, and the 26S proteasome? Arch Biochem Biophys. 1999 May 01; 365(1):31-44. PMID: 10222036.
      View in: PubMed
    39. He K, Bornheim LM, Falick AM, Maltby D, Yin H, Correia MA. Identification of the heme-modified peptides from cumene hydroperoxide-inactivated cytochrome P450 3A4. Biochemistry. 1998 Dec 15; 37(50):17448-57. PMID: 9860860.
      View in: PubMed
    40. Wang H, Dick R, Yin H, Licad-Coles E, Kroetz DL, Szklarz G, Harlow G, Halpert JR, Correia MA. Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry. 1998 Sep 08; 37(36):12536-45. PMID: 9730826.
      View in: PubMed
    41. Licad-Coles E, He K, Yin H, Correia MA. Cytochrome P450 2C11: Escherichia coli expression, purification, functional characterization, and mechanism-based inactivation of the enzyme. Arch Biochem Biophys. 1997 Feb 01; 338(1):35-42. PMID: 9015385.
      View in: PubMed
    42. He K, He YA, Szklarz GD, Halpert JR, Correia MA. Secobarbital-mediated inactivation of cytochrome P450 2B1 and its active site mutants. Partitioning between heme and protein alkylation and epoxidation. J Biol Chem. 1996 Oct 18; 271(42):25864-72. PMID: 8824218.
      View in: PubMed
    43. Ren S, Liu H, Licad E, Correia MA. Expression of rat liver tryptophan 2,3-dioxygenase in Escherichia coli: structural and functional characterization of the purified enzyme. Arch Biochem Biophys. 1996 Sep 01; 333(1):96-102. PMID: 8806758.
      View in: PubMed
    44. He K, Falick AM, Chen B, Nilsson F, Correia MA. Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital. Chem Res Toxicol. 1996 Apr-May; 9(3):614-22. PMID: 8728507.
      View in: PubMed
    45. Bornheim LM, Kim KY, Chen B, Correia MA. Microsomal cytochrome P450-mediated liver and brain anandamide metabolism. Biochem Pharmacol. 1995 Aug 25; 50(5):677-86. PMID: 7669071.
      View in: PubMed
    46. Correia MA, Yao K, Allentoff AJ, Wrighton SA, Thompson JA. Interactions of peroxyquinols with cytochromes P450 2B1, 3A1, and 3A5: influence of the apoprotein on heterolytic versus homolytic O-O bond cleavage. Arch Biochem Biophys. 1995 Mar 10; 317(2):471-8. PMID: 7893165.
      View in: PubMed
    47. Liu H, Correia MA. Cobaltous chloride-mediated induction of rat hepatic tryptophan 2,3-dioxygenase: implications for the use of the enzyme to probe the hepatic free heme pool. Cell Mol Biol (Noisy-le-grand). 1994 Nov; 40(7):881-9. PMID: 7849555.
      View in: PubMed
    48. Sugiyama K, Correia MA, Thummel KE, Nagata K, Darbyshire JF, Osawa Y, Gillette JR. pH-dependent one- and two-electron oxidation of 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine catalyzed by horseradish peroxidase. Chem Res Toxicol. 1994 Sep-Oct; 7(5):633-42. PMID: 7841342.
      View in: PubMed
    49. Bornheim LM, Everhart ET, Li J, Correia MA. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol. 1994 Jul 05; 48(1):161-71. PMID: 8043019.
      View in: PubMed
    50. Halpert JR, Guengerich FP, Bend JR, Correia MA. Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol. 1994 Apr; 125(2):163-75. PMID: 8171425.
      View in: PubMed
    51. Bornheim LM, Kim KY, Chen B, Correia MA. The effect of cannabidiol on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism. Biochem Biophys Res Commun. 1993 Dec 15; 197(2):740-6. PMID: 8267610.
      View in: PubMed
    52. Prueksaritanont T, Correia MA, Rettie AE, Swinney DC, Thomas PE, Benet LZ. Cyclosporine metabolism by rat liver microsomes. Evidence for involvement of enzyme(s) other than cytochromes P-450 3A. Drug Metab Dispos. 1993 Jul-Aug; 21(4):730-7. PMID: 8104135.
      View in: PubMed
    53. Bornheim LM, Everhart ET, Li J, Correia MA. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol. 1993 Mar 24; 45(6):1323-31. PMID: 8466552.
      View in: PubMed
    54. Yao K, Falick AM, Patel N, Correia MA. Cumene hydroperoxide-mediated inactivation of cytochrome P450 2B1. Identification of an active site heme-modified peptide. J Biol Chem. 1993 Jan 05; 268(1):59-65. PMID: 8416964.
      View in: PubMed
    55. Lewis S, Korsmeyer KK, Correia MA. Matrix-assisted laser desorption mass spectrometry of cytochromes P450. Rapid Commun Mass Spectrom. 1993 Jan; 7(1):16-9. PMID: 8428024.
      View in: PubMed
    56. Correia MA, Davoll SH, Wrighton SA, Thomas PE. Degradation of rat liver cytochromes P450 3A after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: characterization of the proteolytic system. Arch Biochem Biophys. 1992 Sep; 297(2):228-38. PMID: 1497342.
      View in: PubMed
    57. Correia MA, Yao K, Wrighton SA, Waxman DJ, Rettie AE. Differential apoprotein loss of rat liver cytochromes P450 after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: a case for distinct proteolytic mechanisms? Arch Biochem Biophys. 1992 May 01; 294(2):493-503. PMID: 1567205.
      View in: PubMed
    58. Underwood MC, Cashman JR, Correia MA. Specifically designed thiosteroids as active-site-directed probes for functional dissection of rat liver cytochrome P450 3A isozymes. Chem Res Toxicol. 1992 Jan-Feb; 5(1):42-53. PMID: 1581535.
      View in: PubMed
    59. Decker CJ, Cashman JR, Sugiyama K, Maltby D, Correia MA. Formation of glutathionyl-spironolactone disulfide by rat liver cytochromes P450 or hog liver flavin-containing monooxygenases: a functional probe of two-electron oxidations of the thiosteroid? Chem Res Toxicol. 1991 Nov-Dec; 4(6):669-77. PMID: 1807450.
      View in: PubMed
    60. Bornheim LM, Correia MA. Purification and characterization of the major hepatic cannabinoid hydroxylase in the mouse: a possible member of the cytochrome P-450IIC subfamily. Mol Pharmacol. 1991 Aug; 40(2):228-34. PMID: 1875910.
      View in: PubMed
    61. Correia MA. Cytochrome P450 turnover. Methods Enzymol. 1991; 206:315-25. PMID: 1784218.
      View in: PubMed
    62. Bornheim LM, Correia MA. Selective inactivation of mouse liver cytochrome P-450IIIA by cannabidiol. Mol Pharmacol. 1990 Sep; 38(3):319-26. PMID: 2402224.
      View in: PubMed
    63. Sugiyama K, Yao K, Rettie AE, Correia MA. Inactivation of rat hepatic cytochrome P-450 isozymes by 3,5-dicarbethoxy- 2,6-dimethyl-4-ethyl-1,4-dihydropyridine. Chem Res Toxicol. 1989 Nov-Dec; 2(6):400-10. PMID: 2519730.
      View in: PubMed
    64. Bornheim LM, Correia MA. Effect of cannabidiol on cytochrome P-450 isozymes. Biochem Pharmacol. 1989 Sep 01; 38(17):2789-94. PMID: 2550010.
      View in: PubMed
    65. Bornheim LM, Correia MA. Purification and characterization of a mouse liver cytochrome P-450 induced by cannabidiol. Mol Pharmacol. 1989 Sep; 36(3):377-83. PMID: 2779523.
      View in: PubMed
    66. Decker CJ, Rashed MS, Baillie TA, Maltby D, Correia MA. Oxidative metabolism of spironolactone: evidence for the involvement of electrophilic thiosteroid species in drug-mediated destruction of rat hepatic cytochrome P450. Biochemistry. 1989 Jun 13; 28(12):5128-36. PMID: 2765527.
      View in: PubMed
    67. Correia MA, Lunetta JM. Acute hepatic heme depletion: impaired gluconeogenesis in rats. Semin Hematol. 1989 Apr; 26(2):120-7. PMID: 2471273.
      View in: PubMed
    68. Lunetta JM, Sugiyama K, Correia MA. Secobarbital-mediated inactivation of rat liver cytochrome P-450b: a mechanistic reappraisal. Mol Pharmacol. 1989 Jan; 35(1):10-7. PMID: 2913483.
      View in: PubMed
    69. Correia MA, Sugiyama K, Yao KQ. Degradation of rat hepatic cytochrome P-450p. Drug Metab Rev. 1989; 20(2-4):615-28. PMID: 2680399.
      View in: PubMed
    70. Pascoe GA, Correia MA. Role of gastrin/pentagastrin in regulation of intestinal cytochrome P-450. Comp Biochem Physiol C. 1988; 90(1):41-6. PMID: 2904872.
      View in: PubMed
    71. Correia MA, Decker C, Sugiyama K, Caldera P, Bornheim L, Wrighton SA, Rettie AE, Trager WF. Degradation of rat hepatic cytochrome P-450 heme by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine to irreversibly bound protein adducts. Arch Biochem Biophys. 1987 Nov 01; 258(2):436-51. PMID: 3674884.
      View in: PubMed
    72. Bornheim LM, Underwood MC, Caldera P, Rettie AE, Trager WF, Wrighton SA, Correia MA. Inactivation of multiple hepatic cytochrome P-450 isozymes in rats by allylisopropylacetamide: mechanistic implications. Mol Pharmacol. 1987 Aug; 32(1):299-308. PMID: 3302670.
      View in: PubMed
    73. Correia MA, Litman DA, Lunetta JM. Drug-induced modulations of hepatic heme metabolism. Neurological consequences. Ann N Y Acad Sci. 1987; 514:248-55. PMID: 3442388.
      View in: PubMed
    74. Bornheim LM, Correia MA. Fractionation and purification of hepatic microsomal cytochrome P-450 isoenzymes from phenobarbital-pretreated rats by h.p.l.c. A convenient tool for screening of isoenzymes inactivated by allylisopropylacetamide. Biochem J. 1986 Nov 01; 239(3):661-9. PMID: 3827818; PMCID: PMC1147337.
      View in: PubMed, PubMed Central
    Almira's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (327) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (7) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (60) people
    _
    Same Department
    Search Department
    ↑